SBIO
ALPS Medical Breakthroughs ETF
📎 Investment Objective
The ALPS Medical Breakthroughs ETF (SBIO) seeks to track the performance of the Poliwogg Medical Breakthroughs Index, which is designed to identify small- and mid-cap companies in the biotechnology and pharmaceutical sectors that have one or more drugs in either Phase II or Phase III clinical trials.
Overview
ETF tracking ALPS Medical Breakthroughs ETF
Performance
Price Chart
Investment Summary
📎 Investment Objective
The ALPS Medical Breakthroughs ETF (SBIO) seeks to track the performance of the Poliwogg Medical Breakthroughs Index, which is designed to identify small- and mid-cap companies in the biotechnology and pharmaceutical sectors that have one or more drugs in either Phase II or Phase III clinical trials.
🎯 Investment Strategy
The fund invests at least 80% of its net assets in securities that are constituents of the underlying index. The index is composed of small- and mid-cap companies that have at least one drug candidate in the clinical trial pipeline, with a focus on Phase II and Phase III trials.
✨ Key Features
- Focuses on small- and mid-cap biotechnology and pharmaceutical companies with promising drug candidates in late-stage clinical trials
- Provides exposure to the potentially high-growth medical breakthroughs sector
- Diversified portfolio across multiple companies and drug development pipelines
- Low expense ratio of 0.00%
⚠️ Primary Risks
- High volatility and risk due to the speculative nature of the biotechnology and pharmaceutical sectors
- Concentration risk as the fund is focused on a specific industry
- Potential for delays or failures in drug development and approval processes
- Liquidity risk for smaller, less-traded companies in the portfolio
👤 Best For
The ALPS Medical Breakthroughs ETF may be suitable for investors with a long-term investment horizon and a higher risk tolerance who are seeking exposure to the potentially high-growth medical breakthroughs sector. Investors should be aware of the increased volatility and risks associated with this type of fund.